| Document |
Document Title |
|
JP2015533372A |
Polypeptides that are capable of crossing cell membranes and entering the intracellular environment and are suitable for prophylactic, therapeutic or diagnostic use as well as screening and detection are provided herein. Nucleic Acids En...
|
|
JP5779787B2 |
The present invention relates firstly to the discovery of the previously unknown 24-membered cyclooctadepsipeptides PF1022-V, PF1022-W, XRB-C894, XRB-C942, XRB-C976, XRB-C1010, XRB-C1044, XRB-E922, XRB-E956, XRB-E990, XRB-E1024, XRB-S958...
|
|
JP2015147779A |
To provide compositions containing calcium-binding peptides.The present invention discloses a class of compounds comprising peptides of the sequence (X-Y-Z), where X is an amino acid selected from aspartic acid, glutamic acid, asparagine...
|
|
JP5758806B2 |
At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis...
|
|
JP2015517485A |
The present invention relates to an isolated compound of formula (1), a derivative thereof, or a pharmaceutically acceptable salt thereof. The present invention also includes all isomers and tautomers of the compound of formula (1) or it...
|
|
JP5686468B2 |
The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vi...
|
|
JPWO2012176909A1 |
A tripropeptin derivative represented by either the following general formula (1) or the following general formula (2) or a pharmacologically acceptable salt thereof. However, in the general formula (1), R1 represents an organic group ha...
|
|
JP5670914B2 |
The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against ...
|
|
JP5657594B2 |
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their productions.
|
|
JP5656407B2 |
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
|
|
JP2014532071A |
The present invention relates to protocells for specific targets of hepatocellular carcinoma cells and other cancer cells, the protocells being directed against a nanoporous silica core with a supported lipid bilayer, at least one agent,...
|
|
JP2014205714A |
To provide an alternative immunosuppressant having low cytotoxicity characteristics and controllable side effects.A depsipeptide having a structure (I) and a homolog thereof are disclosed, where m, n, p, q, X, R1, R2 and R3 are as define...
|
|
JP2014177479A |
To provide a method for treating individuals suffering from non-small cell lung cancer and prostate cancer.A method includes a stage of administering, for a period of time, a MUC-1-based formulation comprising a liposome containing at le...
|
|
JP2014159449A |
To achieve the effective control of endoparasites.The present invention relates to didepsipeptides defined by a specific general formula and their use for the control of endoparasites.
|
|
JP5579703B2 |
The subject application pertains to a compound of structure IX or X: or a pharmaceutically acceptable salt thereof, wherein: X is -C(=O)N(R10)- or -CH(OPr3) -; R7, R9 and R10 are the same or different and represent hydrogen or an amino a...
|
|
JP5558710B2 |
Compounds which are FK228 analogues of the general formula (I) or (I′), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amin...
|
|
JP2014114298A |
To provide human MAML polypeptides in which modified polypeptides bind to a complex that includes ICN and CSL.These cross-linked polypeptides contain at least two modified amino acids that together form an internal cross-link or tether t...
|
|
JP2014114318A |
To provide a novel diagnostic compound of diseases associated with vascular cell adhesion molecule-1 (VCAM) expression, to provide a preparation method of the same, and to provide a use of the same in medical imaging.There is provided a ...
|
|
JP5520824B2 |
The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.
|
|
JP5462493B2 |
|
|
JP5462494B2 |
|
|
JP2014037351A |
To provide a new pest control agent having pest control activity, a compound used as an effective component thereof, and a production method thereof.Provided are a PF1442 substance represented by the formula (3): (where, R1 represents a ...
|
|
JP5401459B2 |
The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7.
|
|
JP5396016B2 |
|
|
JP5386169B2 |
The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nuc...
|
|
JP2013544777A |
The present invention relates to a composition comprising a Nucant multivalent synthetic compound and a glycosaminoglycan, the admixture of both compounds forming microspheres comprising both compounds, as well as their use for the treat...
|
|
JP2013544798A |
The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.
|
|
JP5372096B2 |
New analogues of kahalalide F are provided.
|
|
JP5335677B2 |
This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to...
|
|
JP2013147429A |
To provide a compound which is useful as antifungal agent.In order to investigate the compound produced by a microorganism, microorganisms of the genus Paenibacillus are sampled and, from a culture medium thereof, a depsipeptide compound...
|
|
JP5248610B2 |
The present invention relates to novel ²-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid mo...
|
|
JP2013136597A |
To provide cyclosporine analogues that posse enhanced efficacy and reduced toxicity compared with presently known cyclosporine.There are provided cis and trans-isomers of cyclosporine A analogs referred to as ISATX247, and derivatives th...
|
|
JP2013107902A |
To provide alternate immunosuppressive agents with low cytotoxicity profiles and manageable side effects.Depsipeptides and congeners thereof are disclosed having structure (I): wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. ...
|
|
JP5196788B2 |
The invention relates to cyclic depsipeptides, especially 18-membered cyclohexadepsipeptides of general formula (I) and the salts thereof, wherein R1 represents nitrobenzyl or R'R''N-benzyl-wherein R' and R'' independently represent hydr...
|
|
JP5188665B2 |
A process is provided for preparing kahalalide F and which leads to other kahalalide mimic compounds having useful biological activity.
|
|
JP5178731B2 |
A compound of the general Structure (VII) or (VIII) including isoteres and pharmaceutically acceptable salts thereof, wherein R1, R2 (where X=—CONR6—), R3 and R7 are the same or different and each represents an amino-acid side chain ...
|
|
JP5158716B2 |
Disclosed are a compound represented by the general formula (I) below and a polymer compound obtained by polymerizing such a compound. €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒR 1 -Gly-Lac-Pro-R 2 €ƒ€ƒ€ƒ€ƒ€ƒ(I) : where -Gly...
|
|
JP2012240974A |
To provide a method for efficiently producing didemnin B.In the method for producing didemnin B, a microorganism belonging to Tistrella mobilis capable of producing didemnin B is cultivated, and didemnin B is extracted from the culture.
|
|
JP5073518B2 |
To provide a siderophore having high ability to bind to iron ion and thus assisting the stable existence of iron ion in its aqueous solution, and to provide a marine environment modifier containing the siderophore. The siderophore is a c...
|
|
JP4997293B2 |
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their productions.
|
|
JP2012140432A |
To provide novel lipopeptide compounds.This invention relates to: the novel lipopeptide compounds which have antibacterial activity; pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial com...
|
|
JP2012512839A |
Compounds of general formula I: wherein R1-R15 and n take permitted meanings for use in the treatment of cancer.
|
|
JP2012510430A |
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
|
|
JP2012509902A |
The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for...
|
|
JP2012051899A |
To provide a novel antitumor compound.There are provided a kahalalide F-based compound expressed by formula 1 and a pharmaceutically acceptable salt thereof.
|
|
JP2012031187A |
To provide a more required antitumoral compound, especially a more required kahalalide compound having improved characteristics.There is provided a new analogue of kahalalide F.
|
|
JP4874796B2 |
New analogues of kahalalide F are provided.
|
|
JP2012503025A |
The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
|
|
JP4860820B2 |
The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wh...
|
|
JP4843614B2 |
The invention relates to nonadepsipeptides and processes for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
|
